
    
      In this multicenter trial, the safety and efficacy of magnetic resonance imaging (MRI) for
      visualization of the coronary arteries (CMRA, coronary magnetic resonance angiography) with
      MS-325. MS-325 is a new blood pool radiological contrast agent which will be assessed as part
      of a phase II feasibility study. The Laboratory of Cardiac Energetics in collaboration with
      the Department of Cardiology at the George Washington Hospital Center will be one of the six
      participating sites for this study.
    
  